We are thrilled to announce that Deepflare is partnering with Ceva Santé Animale to pursue AI-enhanced Vaccine Discovery. This collaboration is pivotal, combining our advanced AI capabilities with Ceva's extensive expertise in therapeutic development to design breakthrough next-generation vaccines. The partnership aims to unlock significant technological potential and market opportunities for both companies, driving innovation across the health industry and accessing a market worth over $10 billion for both companies. This milestone project will enable us to gain invaluable insights into vaccine discovery and contribute to the development of life-saving products by a global leader in the field, bringing us a step closer to achieving our goal of creating a world where no disease is incurable. Thank you Thomas Lewiner, John El-Attrache, Stanisław Giziński, Grzegorz Preibisch & Piotr Grzegorczyk. We are all excited for a safer future! #aivaccines #SantéAnimale #OneCeva #machinelearning #generativeai #software
Deepflare
Badania w zakresie biotechnologii
Cambridge, Massachusetts 1414 obserwujących
Building AI systems to help companies optimize T-cell response.
Informacje
At Deepflare, we are developing tools in order to eradicate cancer forever. We were established in 2020 with the simple goal of using AI to combat the problem of virus mutation, expanding our horizons and applications since then. We build systems to help pharmaceutical companies develop better, more effective vaccines faster.
- Witryna
-
https://deepflare.ai/
Link zewnętrzny organizacji Deepflare
- Branża
- Badania w zakresie biotechnologii
- Wielkość firmy
- 2–10 pracowników
- Siedziba główna
- Cambridge, Massachusetts
- Rodzaj
- Spółka prywatna
- Data założenia
- 2022
Lokalizacje
-
Główna
Cambridge, Massachusetts US
-
Warsaw, PL
Pracownicy Deepflare
Aktualizacje
-
We're excited to be listed as one of the top European startups to watch in Drug Discovery by Sifted! It's inspiring to see the progress made in this space. We will be sharing more news about our own soon, stay tuned! If you work on vaccines or immunotherapy development, contact us! We're always happy to talk and discuss how we could collaborate. Let's create a future where we can combat any disease, together! #techbio #drugdiscovery #cancer #AI
-
-
We are hiring! 🚀 We are excited to announce a new job opening for a Machine Learning Engineer at Deepflare. If you have 2+ years of experience in Deep Learning and are passionate about TechBio, then we would love to hear from you! Let's make a difference in the future of immunotherapy development together. Learn more and apply here via the link below. #Hiring #JobOpening #JoinOurTeam #CareerOpportunity
-
Deepflare ponownie to opublikował(a)
Guten Tag, Berlin! 🔥 I have just arrived here for a few days; please message me to discuss the intersection of AI and Bio, techbio, and the future of drug discovery & cancer treatment! 🚀 Let's make some memorable connections. #berlin #techbio #immunotherapies #deepflare #ai
-
Deepflare ponownie to opublikował(a)
Deepflare will be attending the Neoantigen Summit in Amsterdam next week! 🔥 We will discuss the latest advancements with our partners and key players in the field. Only by working together can we advance the human effort to combat cancer and ultimately eliminate the fear of it once and for all. #cancer #collaboration #partnership #tcell #innovation
-
-
Deepflare will be attending the Neoantigen Summit in Amsterdam next week! 🔥 We will discuss the latest advancements with our partners and key players in the field. Only by working together can we advance the human effort to combat cancer and ultimately eliminate the fear of it once and for all. #cancer #collaboration #partnership #tcell #innovation
-
-
We are excited to introduce pepRank, a web service designed to streamline the discovery of immunogenic peptides! 🚀 The impact of it is huge, reducing the necessary number of experiments by up to 50% in comparison to currently used solutions. The service is now available free of charge to academic researchers. The T-cell response plays a crucial role in vaccine efficacy, making the precise identification of epitopes critical for vaccine design. Traditionally, coming up with initial peptides to test experimentally was done using simple heuristics or simple tools, many of which are biased. The method we developed effectively mitigates biases and limitations occurring in previous solutions for years, including validation on synthetic peptides or using peptides from a training set for validation. To overcome these challenges, we created a new dataset and implemented rigorous validation processes. Our approach ensures the model's ability to predict effectively entirely new Human Leukocyte Antigens (HLAs) and peptides, never seen by the model. The results demonstrate a clear advancement over all existing solutions, reaching new state-of-the-art status. Exciting times ahead of us 🔥 #CancerResearch #AIInHealthcare #MedicalInnovation #Deepflare #Oncology #VaccineDevelopment #HealthTech #FutureOfMedicine